Safety notice

MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication

Safety notice from a federal regulator

Headline as published by U.S. Food and Drug Administration (MedWatch) on Nov 9, 2026; collected by the wire Nov 9, 2026, 1:15 PM ET.

Read at U.S. Food and Drug Administration (MedWatch)

FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication

From U.S. Food and Drug Administration (MedWatch)’s feed

Coverage

  1. U.S. Food and Drug Administration (MedWatch) Federal regulators

    MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication

Named in this story

Topics

Explore the named firms, organizations and MDL dockets above. Sources and method